Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Overexpression of Eag1 potassium channels in clinical tumours.

Authors: Hemmerlein, B  Weseloh, RM  Mello de Queiroz, F  Knotgen, H  Sanchez, A  Rubio, ME  Martin, S  Schliephacke, T  Jenke, M  Heinz-Joachim-Radzun, M  Stuhmer, W  Pardo, LA 
Citation: Hemmerlein B, etal., Mol Cancer. 2006 Oct 5;5:41.
Pubmed: (View Article at PubMed) PMID:17022810
DOI: Full-text: DOI:10.1186/1476-4598-5-41

BACKGROUND: Certain types of potassium channels (known as Eag1, KCNH1, Kv10.1) are associated with the production of tumours in patients and in animals. We have now studied the expression pattern of the Eag1 channel in a large range of normal and tumour tissues from different collections utilising molecular biological and immunohistochemical techniques. RESULTS: The use of reverse transcription real-time PCR and specifically generated monoclonal anti-Eag1 antibodies showed that expression of the channel is normally limited to specific areas of the brain and to restricted cell populations throughout the body. Tumour samples, however, showed a significant overexpression of the channel with high frequency (up to 80% depending on the tissue source) regardless of the detection method (staining with either one of the antibodies, or detection of Eag1 RNA). CONCLUSION: Inhibition of Eag1 expression in tumour cell lines reduced cell proliferation. Eag1 may therefore represent a promising target for the tailored treatment of human tumours. Furthermore, as normal cells expressing Eag1 are either protected by the blood-brain barrier or represent the terminal stage of normal differentiation, Eag1 based therapies could produce only minor side effects.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
RGD Object Information
RGD ID: 9693723
Created: 2015-02-12
Species: All species
Last Modified: 2015-02-12
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.